A Dual Concentration-Tailored Cytokine-Chemo Nanosystem to Alleviate Multidrug Resistance and Redirect Balance of Cancer Proliferation and Apoptosis

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2023 Aug 3

PMID 37534057

Authors

Yu Hsia

Maharajan Sivasubramanian

Chia-Hui Chu

Yao-Chen Chuang

Yiu-Kay Lai

Leu-Wei Lo

Affiliations

Soon will be listed here.

Abstract

Background: Cancer multidrug resistance (MDR) is an important factor that severely affects the chemotherapeutic efficacy. Among various methods to bypass MDR, usage of cytokines, such as tumor necrosis factor alpha (TNFα) is attractive, which exerts antitumor effects of immunotherapeutic response and apoptotic/proinflammatory pathways. Nevertheless, the challenges remain how to implement targeted delivery of TNFα to reduce toxicity and manifest the involved signaling mechanism that subdues MDR.

Methods: We synthesized a multifunctional nanosytem, in which TNFα covalently bound to doxorubicin (Dox)-loaded pH-responsive mesoporous silica nanoparticles (MSN) through bi-functional polyethylene glycol (TNFα-PEG-MSN-Hydrazone-Dox) as a robust design to overcome MDR.

Results: The salient features of this nanoplatform are: 1) by judicious tailoring of TNFα concentration conjugated on MSN, we observed it could lead to a contrary effect of either proliferation or suppression of tumor growth; 2) the MSN-TNFα at higher concentration serves multiple functions, besides tumor targeting and inducer of apoptosis through extrinsic pathway, it inhibits the expression level of p-glycoprotein (P-gp), a cell membrane protein that functions as a drug efflux pump; 3) the enormous surface area of MSN provides for TNFα functionalization, and the nanochannels accommodate chemotherapeutics, Dox; 4) targeted intracellular release of Dox through the pH-dependent cleavage of hydrazone bonds induces apoptosis by the specific intrinsic pathway; and 5) TNFα-PEG-MSN-Hydrazone-Dox (MSN-Dox-TNFα) could infiltrate deep into the 3D spheroid tumor model through disintegration of tight junction proteins. When administered intratumorally in a Dox-resistant mouse tumor model, MSN-Dox-TNFα exhibited a synergistic therapeutic effect through the collective performances of TNFα and Dox.

Conclusion: We hereby develop and demonstrate a multifunctional MSN-Dox-TNFα system with concentration-tailored TNFα that can abrogate the drug resistance mechanism, and significantly inhibit the tumor growth through both intrinsic and extrinsic apoptosis pathways, thus making it a highly potential nanomedicine translated in the treatment of MDR tumors.

Citing Articles

PEG-Polymeric Nanocarriers Alleviate the Immunosuppressive Effects of Free 4-Thiazolidinone-Based Chemotherapeutics on T Lymphocyte Function and Cytokine Production.

Tulinska J, Kobylinska L, Lehotska Mikusova M, Babincova J, Mitina N, Rollerova E Int J Nanomedicine. 2025; 19:14021-14041.

PMID: 39742092 PMC: 11687095. DOI: 10.2147/IJN.S479137.

References

Wang X, Hong X, Zhu L, Wang Y, Bao J, Liu L . Tumor necrosis factor alpha promotes the proliferation of human nucleus pulposus cells via nuclear factor-κB, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. Exp Biol Med (Maywood). 2014; 240(4):411-7. PMC: 4935371. DOI: 10.1177/1535370214554533. View

Chapman P, Lester T, Casper E, GABRILOVE J, Wong G, Kempin S . Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1987; 5(12):1942-51. DOI: 10.1200/JCO.1987.5.12.1942. View

Zhou Y, Quan G, Wu Q, Zhang X, Niu B, Wu B . Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B. 2018; 8(2):165-177. PMC: 5926503. DOI: 10.1016/j.apsb.2018.01.007. View

Chen N, Souris J, Cheng S, Chu C, Wang Y, Konda V . Lectin-functionalized mesoporous silica nanoparticles for endoscopic detection of premalignant colonic lesions. Nanomedicine. 2017; 13(6):1941-1952. PMC: 5673680. DOI: 10.1016/j.nano.2017.03.014. View

STEVENSON B, Siliciano J, Mooseker M, Goodenough D . Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol. 1986; 103(3):755-66. PMC: 2114282. DOI: 10.1083/jcb.103.3.755. View

Lu J, Liong M, Li Z, Zink J, Tamanoi F . Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010; 6(16):1794-805. PMC: 2952648. DOI: 10.1002/smll.201000538. View

Ravi Kumar M . Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci. 2000; 3(2):234-58. View

Walther W, Kobelt D, Bauer L, Aumann J, Stein U . Chemosensitization by diverging modulation by short-term and long-term TNF-α action on ABCB1 expression and NF-κB signaling in colon cancer. Int J Oncol. 2015; 47(6):2276-85. DOI: 10.3892/ijo.2015.3189. View

Paciotti G, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin R . Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004; 11(3):169-83. DOI: 10.1080/10717540490433895. View

10.

van der Veen A, Eggermont A, Seynhaeve A, van Tiel , Ten Hagen T . Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer. 1998; 77(6):901-6. DOI: 10.1002/(sici)1097-0215(19980911)77:6<901::aid-ijc17>3.0.co;2-3. View

11.

Scholzen T, Gerdes J . The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182(3):311-22. DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9. View

12.

Papa S, Zazzeroni F, Pham C, Bubici C, Franzoso G . Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci. 2004; 117(Pt 22):5197-208. DOI: 10.1242/jcs.01483. View

13.

Lee C, Cheng S, Huang I, Souris J, Yang C, Mou C . Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew Chem Int Ed Engl. 2010; 49(44):8214-9. DOI: 10.1002/anie.201002639. View

14.

Haddick L, Zhang W, Reinhard S, Moller K, Engelke H, Wagner E . Particle-Size-Dependent Delivery of Antitumoral miRNA Using Targeted Mesoporous Silica Nanoparticles. Pharmaceutics. 2020; 12(6). PMC: 7355705. DOI: 10.3390/pharmaceutics12060505. View

15.

Berraondo P, Sanmamed M, Ochoa M, Etxeberria I, Aznar M, Perez-Gracia J . Cytokines in clinical cancer immunotherapy. Br J Cancer. 2018; 120(1):6-15. PMC: 6325155. DOI: 10.1038/s41416-018-0328-y. View

16.

Foroozandeh P, Abdul Aziz A . Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles. Nanoscale Res Lett. 2018; 13(1):339. PMC: 6202307. DOI: 10.1186/s11671-018-2728-6. View

17.

Jafari S, Derakhshankhah H, Alaei L, Fattahi A, Shiri Varnamkhasti B, Saboury A . Mesoporous silica nanoparticles for therapeutic/diagnostic applications. Biomed Pharmacother. 2018; 109:1100-1111. DOI: 10.1016/j.biopha.2018.10.167. View

18.

Wajant H, Pfizenmaier K, Scheurich P . Tumor necrosis factor signaling. Cell Death Differ. 2003; 10(1):45-65. DOI: 10.1038/sj.cdd.4401189. View

19.

Takada H, Chen N, Mirtsos C, Suzuki S, Suzuki N, Wakeham A . Role of SODD in regulation of tumor necrosis factor responses. Mol Cell Biol. 2003; 23(11):4026-33. PMC: 155221. DOI: 10.1128/MCB.23.11.4026-4033.2003. View

20.

Vivero-Escoto J, Slowing I, Trewyn B, Lin V . Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 2010; 6(18):1952-67. DOI: 10.1002/smll.200901789. View